Health TrialsbyHealthPanel

ABCSG R07 Rectal Cancer Registry

ConditionsRectal CancerAdenocarcinoma of Rectum
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAustrian Breast & Colorectal Cancer Study Group

About this trial

In Austria, patients with rectal cancer that has not spread to other parts of the body are typically treated with either total neoadjuvant therapy (TNT) or immunotherapy, depending on their microsatellite status (DNA repair capacity).

However, treatment can vary considerably between hospitals in Austria. These differences may include the type and duration of treatment, as well as the active ingredients used. There are currently no clear recommendations on which exact treatment is best for each specific case.

The aim of this observational study is to collect information on the different treatments used in Austria for patients with localized rectal cancer and to document the outcomes of these treatments.

Only information and samples collected as part of the patients' routine care will be used for the study. Participation in the study will not change or affect the treatment chosen by the treating physician.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Female and male participants with age >= 18 years

Signed informed consent obtained prior to registration of the participant.

Localized rectal cancer treated with TNT or localized, non-metastatic dMMR/MSI-H rectal cancer, irrespective of treatment

Disqualifiers

Distant metastases at primary diagnosis

Trial population

Multicenter study in Austria of patients with localized non-metastatic rectal cancer treated with total neoadjvuant therapy or dMMR/MSI-H status

Trial design

Design model

Cohort

Time perspective

Other

Treatments tested in this trial

Not listed

Trial groups

600 Participants
are grouped into 2 trial groups
Group A: Retrospective part
Group B: Prospective part

Trial outcomes

Primary outcomes

1

Treatment Responses (clinical standard therapy)

Recording of treatment responses according to clinical standard therapy.

Time frame
At the time of surgery

Secondary outcomes

1

Proportion of different TNT concepts used

Treatment details

Time frame
From therapy start to Surgery
2

Proportion of participants using immunotherapy

Time frame
From therapy start to Surgery
3

Proportion of participants using watch & wait therapy

Time frame
At surgery visit
4

Proportion of the surgical techniques used

Time frame
At surgery

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Austrian Breast & Colorectal Cancer Study Group

Lead sponsor

GlaxoSmithKline

Collaborator

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: